NCT05654779View on ClinicalTrials.gov

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

LCAR-AMDR Cells Product

Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells

Trial Locations (2)

100070

Beijing Gobroad BoRen Hospital, Beijing

300020

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER